Anemia in Chronic Kidney Disease in Non-dialysis Patients Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.
The study consisted of three study periods as follows: - Screening period: up to 6 weeks - Treatment period: minimum 52 weeks (primary treatment period) up to a maximum of 104 weeks (extended treatment period) - Post-Treatment Follow-Up period: 4 weeks ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02021318 -
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
|
Phase 3 |